Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 9, 2024
Distillery Therapeutics

Targeting PRMT3 for HCC antitumor immunity

BioCentury | Aug 2, 2024
Distillery Therapeutics

Inhibiting non-canonical STING activity in neurons for MS

BioCentury | Aug 1, 2024
Distillery Therapeutics

Inhibiting USP8 for cGAS-mediated autoimmune diseases

BioCentury | Aug 1, 2024
Distillery Therapeutics

Inhibiting SMARCAL1 for anti-tumor immunity

BioCentury | Jul 31, 2024
Discovery & Translation

Science Spotlight: CAR tyrosine kinases, disrupting SWI/SNF for lung cancer, and more

BioCentury’s roundup of translational innovations
BioCentury | Jun 6, 2024
Discovery & Translation

Science Spotlight: Engineered CD47 protects CAR T cells from macrophages and more

BioCentury’s roundup of translational innovations
BioCentury | May 2, 2024
Politics, Policy & Law

Biopharma industry pushing for changes to Biosecure Act

Survey of reliance on Chinese CDMOs, report from National Security Commission could convince lawmakers to modify anti-China bills
BioCentury | May 2, 2024
Management Tracks

McDonnell now CEO of Agilent

Plus: Dubensky to lead ImmuneSensor and updates from NORD and Epsilogen
BioCentury | Apr 25, 2024
Product Development

Innate immune activators among first-in-human debuts at AACR

Spotlight on early-stage solid tumor trials with emerging innate immune targets: ALPK1 and ENPP1
BioCentury | Apr 12, 2024
Product Development

Cambrian explosion of ADCs at AACR24

Conference showcases six emerging ADC payload types, and trends in antigen pairs for bispecific ADCs
Items per page:
1 - 10 of 175